Use of ziprasidone in parkinsonian patients with psychosis. - Wikidata - awgldk - TriplyDB

Use of ziprasidone in parkinsonian patients with psychosis.

Use of ziprasidone in parkinsonian patients with psychosis.

http://www.wikidata.org/entity/Q46555296

about

Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study.Behavioral effects of levodopa.Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?Pathophysiology and treatment of psychosis in Parkinson's disease: a review.Almost all antipsychotics result in weight gain: a meta-analysis.An update expert opinion on management and research strategies in Parkinson's disease psychosis Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs.The management of psychosis in movement disorder patients.Management of the behavioral aspects of Parkinson's disease.Current approaches to the treatment of Parkinson's disease Treatment options for non-motor symptoms in late-stage Parkinson's disease.Atypical antipsychotic drugs in the treatment of Parkinson's disease.Neuropsychiatric Issues in Parkinson's Disease.A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease.Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson's disease.Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson's disease.

P2860

Q24680260-4FF60906-F4B1-4402-8DF6-C8E221927A0B Q26738456-C2947D91-DCD9-4252-9E64-C1689A85A87B Q33765226-964A05C6-2A8F-4D96-81D3-E242D880FECE Q34452922-A6A7158D-5507-4877-8C8D-3DF6C7AB06AD Q34610593-C68AA68D-344C-4C64-8A0E-3EF4E409D39C Q34610608-37019744-0227-4D58-8DCD-A62AED434E05 Q34661499-1D180AC6-64A2-4FF2-8943-B713CDC14C09 Q35154278-CE033E68-6096-4364-87CA-99D043D45F57 Q36425995-36342F64-1F2C-468E-A329-E40C6559CA96 Q36808034-A4413661-971C-40FA-A3A9-76A52CC89621 Q36847271-A3BACBFF-73CF-4862-8ECD-6C9EA7DE4749 Q36876438-FEA225D0-4024-4412-947F-2FC6F3419604 Q37098986-F8343EEE-288D-4C42-BDAA-3941DE6CC979 Q37957772-CF159F07-171F-4E34-B688-87BE0E348CB7 Q38799051-74E7AD28-53D3-435A-98ED-361172AF290E Q41812925-7B284AC5-AF75-47BE-BB35-878DEEC03331 Q42227533-95B9BB34-4D31-426B-966F-C8BC463847FF Q44836147-1FA41B19-600D-44BC-84CF-AC4ABB701A7E

P2860

Use of ziprasidone in parkinsonian patients with psychosis.

http://www.wikidata.org/entity/Q46555296

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Use of ziprasidone in parkinsonian patients with psychosis.

@en

Use of ziprasidone in parkinsonian patients with psychosis.

@nl

type

label

Use of ziprasidone in parkinsonian patients with psychosis.

@en

Use of ziprasidone in parkinsonian patients with psychosis.

@nl

prefLabel

Use of ziprasidone in parkinsonian patients with psychosis.

@en

Use of ziprasidone in parkinsonian patients with psychosis.

@nl

P1433

Q46555296-0CE5EE00-F4AB-4A15-B4F4-F73321F2A852

P1476

Q46555296-F2895BDA-B24E-4B59-9272-48DC25AC33AB

P2093

Q46555296-0476F9AB-26B7-4DEA-AEEB-5CD27D0F3076

Q46555296-0EB497FB-C9FE-4081-B3AE-0F830BC96556

Q46555296-179F8861-AD52-4214-88B3-CC9B8CE0F7B1

Q46555296-341E7728-7A32-4BE1-BCD3-57FC54A072EF

Q46555296-A43D2BF8-F650-4EDD-965F-04D04406F8D6

Q46555296-B19BE1BF-6175-4206-AF67-B16A6A63B1A3

Q46555296-CA8566A9-5546-4A7A-A2FB-B7EB7A89AEA1

Q46555296-D076F0E9-2A48-4CDB-86BE-B48175F90511

P304

Q46555296-5A7A21E7-1936-42FA-BF1E-3375D8E9F005

P31

Q46555296-07A85C18-6377-4BF8-BD99-3E0C68FCC8BD

P356

Q46555296-0C7D5B4C-28AA-4ED4-B700-45D118C6B347

P433

Q46555296-B9E31645-088E-4228-8766-E2B5512482FB

P478

Q46555296-673DC4C4-4C0A-46FE-8E45-9ABBBE6FC7E0

P50

Q46555296-10953825-F5D6-401A-8C6A-321260AC9058

Q46555296-82E6367A-C709-43D0-BED9-CA724D71735D

P577

Q46555296-9ABDB8E4-DA90-4B59-BF48-A4D739EE43EA

P5875

Q46555296-B8F01683-EA25-4529-BC30-DCB5EBC4E316

P698

Q46555296-D47CC968-FCC6-49A9-88F1-BD30AD425163

P921

Q46555296-2069AA28-0E44-4612-A905-8757597BFD91

Q46555296-D7814B9C-D4F0-4509-B67B-3939ADB5EC7F

P356

01.WNF.0000164297.91643.FF

P1433

Clinical Neuropharmacology

P1476

Use of ziprasidone in parkinsonian patients with psychosis

@en

P2093

Elena Lezcano

http://www.w3.org/2001/XMLSchema#string

Fernando Velasco

http://www.w3.org/2001/XMLSchema#string

Idoia Rouco

http://www.w3.org/2001/XMLSchema#string

Isidro Allue

http://www.w3.org/2001/XMLSchema#string

Juan J Zarranz

http://www.w3.org/2001/XMLSchema#string

M C Lachen

http://www.w3.org/2001/XMLSchema#string

Roberto Ciordia

http://www.w3.org/2001/XMLSchema#string

Sabas Boyero

http://www.w3.org/2001/XMLSchema#string

P304

111-114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.WNF.0000164297.91643.FF

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Juan Carlos Gómez-Esteban

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7778698

http://www.w3.org/2001/XMLSchema#string

P698

15965308

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease